New pancreatic cancer pill delivers hope for patients

Date:

Share this article:

Del denne artikel:

A groundbreaking new pill is giving pancreatic cancer patients more time and raising hopes for a long-awaited breakthrough against one of the deadliest forms of cancer.

Cancer touches countless families, but few diagnoses carry the same fear as pancreatic cancer. Often discovered only after it has spread, the disease remains one of the deadliest forms of cancer and has frustrated researchers for decades.

Now, a new study is giving doctors and patients reason for optimism. According to research led by the University of California, Los Angeles (UCLA) and reported by CNN, an experimental drug called daraxonrasib has delivered some of the most encouraging results seen in years for advanced pancreatic cancer, reports Medonet.

A promising discovery

Scientists developed daraxonrasib to target KRAS mutations, genetic changes that drive the growth of most pancreatic cancers. These mutations have long been considered one of the toughest challenges in cancer research.

The drug works by blocking the signals that help cancer cells survive and spread. Researchers believe this targeted approach could open the door to more effective treatments for patients with limited options.

Also read: Cancer symptoms many people overlook in everyday life

Patients living longer

The clinical trial involved around 500 patients whose cancer no longer responded to standard therapies. Participants either received the experimental pill or additional chemotherapy.

The findings were striking. Patients treated with daraxonrasib survived an average of 13.2 months, compared with 6.7 months for those receiving chemotherapy. Researchers also reported fewer severe side effects and improvements in quality of life among many patients taking the new drug.

What comes next?

Health regulators in the United States have already begun an accelerated review of the treatment. Scientists are also investigating whether the drug could help patients diagnosed at earlier stages of the disease.

While experts stress that daraxonrasib is not a cure, many believe it could represent one of the most significant advances in pancreatic cancer treatment in recent years. For patients facing one of medicine’s most difficult diagnoses, that progress alone offers a powerful reason for hope.

Also read: Arthritis drug could become a new treatment for patients with depression

Sources: Medonet

Also read: WHO lowers number of suspected Ebola cases

This article is made and published by Mie Hermansen, who may have used AI in the preparation.

Other articles

A single brain protein may drive aging, and old mice bounced back in about a month

The clue researchers chased sits in a small corner of the brain that quietly steers almost everything else.

The most effective quit-smoking tool has been found

The biggest evidence review yet on how to stop smoking has a clear answer, and it is not the one most doctors still reach for first.

Promising lung cancer drug hits major setback just days before FDA decision

A promising treatment for one of the deadliest lung cancers has hit a setback that experts did not see coming.

Your eyeliner and mascara may be more dangerous than you think, data shows

The familiar tubes sitting on your bathroom shelf are sending people to the emergency room more often than you would guess.

A single brain protein may drive aging, and old mice bounced back in about a month

The clue researchers chased sits in a small corner of the brain that quietly steers almost everything else.

The most effective quit-smoking tool has been found

The biggest evidence review yet on how to stop smoking has a clear answer, and it is not the one most doctors still reach for first.

Promising lung cancer drug hits major setback just days before FDA decision

A promising treatment for one of the deadliest lung cancers has hit a setback that experts did not see coming.